Business Segments · Research And Development Expense
Business Segments — Research And Development Expense
Polaryx Therapeutics, Inc. Business Segments — Research And Development Expense increased by 82.5% to $679.00K in Q1 2026 compared to the prior quarter.
Analysis
How to read this metric
An increase typically signals accelerated clinical trial activity or expanded research efforts, while a decrease may indicate project completion or cost-cutting measures.
Detailed definition
This metric represents the total costs incurred specifically for the research and development of therapeutics targeting...
Peer comparison
Biotech peers typically report R&D expenses segmented by therapeutic area or clinical phase to demonstrate capital allocation efficiency.
Metric ID:
plyx_segment_lysosomal_storage_disorders_research_and_development_expenseHistorical Data
2 periods
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $372.00K | $679.00K |
| QoQ Change | — | +82.5% |
| YoY Change | — | +82.5% |
Range$372.00K – $679.00K
Avg YoY Growth+82.5%
Median YoY Growth+82.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Polaryx Therapeutics, Inc. 's business segments — research and development expense?
- Polaryx Therapeutics, Inc. (PLYX) reported business segments — research and development expense of $679.00K in Q1 2026.
- What does business segments — research and development expense mean?
- The total investment dedicated to researching and developing treatments for lysosomal storage disorders.